ICARES Medicus Inc

As of June 30, 2026, ICARES Medicus Inc carries a market capitalization of 3.10B, placing it among publicly traded companies globally. Its enterprise value stands at 3.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ICARES Medicus Inc's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, ICARES Medicus Inc has 47.16M shares outstanding.

As of June 30, 2026, ICARES Medicus Inc trades at a trailing price-to-earnings ratio of 34.08. The price-to-sales ratio is 2.63, and the price-to-book ratio stands at 1.64.

As of June 30, 2026, ICARES Medicus Inc trades at an EV/EBITDA multiple of 11.59 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.41 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.23B versus a market cap of 3.10B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ICARES Medicus Inc maintains a current ratio of 2.06, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.26, indicating elevated leverage, while an interest coverage ratio of 12.54 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ICARES Medicus Inc posted a return on equity (ROE) of 5.35, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.17 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.01, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.97, useful for judging operating efficiency across full business cycles. The company generates approximately 10.26M in revenue per employee across its workforce of 118.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.26 indicates how many times ICARES Medicus Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ICARES Medicus Inc recorded 82.21M in income tax expense. That works out to an effective tax rate of 72.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 112.72M, leaving 93.56M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, ICARES Medicus Inc's stock has declined approximately 15.27% over the past 52 weeks. The 50-day moving average sits at 70.22, while the 200-day moving average is 66.80.

Over the twelve months ended June 30, 2026, ICARES Medicus Inc generated 1.21B in revenue and converted that into 93.56M in net income, yielding earnings per share of 0.63. EBITDA reached 279.04M, while operating income came in at 115.23M.

As of June 30, 2026, ICARES Medicus Inc holds 792.83M in cash and equivalents against 823.32M in total debt, resulting in a net debt position of 351.43M. Total book value stands at 1.90B, with working capital of 908.34M providing operational flexibility.

ICARES Medicus Inc produced -41.59M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -45.32M in capital expenditures, free cash flow totaled -86.92M - equivalent to -1.79 per share.

Over the twelve months ended June 30, 2026, ICARES Medicus Inc posted a gross margin of 56.46, reflecting its pricing power and cost economics. The operating margin of 9.52 and net profit margin of 7.73 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, ICARES Medicus Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -2.71: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.88, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ICARES Medicus Inc shareholders.

ICARES Medicus Inc's most recent stock split took place on August 26, 2026 with a 10:11 split ratio.

As of June 30, 2026, ICARES Medicus Inc has an Altman Z-Score of 2.90, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.